Alvarez & Marsal Healthcare Industry Group Forms Strategic Alliance with Rondaxe: Alliance Aims to Enhance Efficiency and Effect

Alvarez & Marsal Healthcare Industry Group Forms Strategic Alliance with Rondaxe: Alliance Aims to Enhance Efficiency and Effectiveness of Emerging and Specialty Pharmaceutical Companies
NEW YORK--(BUSINESS WIRE)--Global professional services firm Alvarez & Marsal (A&M) has announced that its Healthcare Industry Group has formed a strategic alliance with Rondaxe, a leading pharmaceutical consultancy, to provide manufacturing, supply chain and compliance services to the pharmaceutical industry. The A&M-Rondaxe alliance will concentrate on delivering integrated services to emerging and specialty companies in the pharmaceutical industry. This latest announcement is part of A&M's effort to expand and deepen its service commitment to clients globally across the entire healthcare continuum.

Together, A&M Healthcare and Rondaxe will employ a diverse group of pharmaceutical industry professionals with expertise in manufacturing operations, supply chain strategy, regulatory affairs, biologicals, natural products, chemical synthesis, drug product and analytical development, quality control and quality assurance.

The A&M-Rondaxe alliance will further augment A&M services across the healthcare continuum, and immediately establish the strategic alliance as an industry innovator seamlessly combining and delivering proven financial and technical services to manufacturing and supply companies. The combined team will consist of professionals who bring proven experience in drug development and commercialization located in Europe and Asia, as well as North America.

"The A&M/Rondaxe alliance will expand A&M's global reach and allow A&M to marry its proven financial, strategic and performance improvement services with Rondaxe's manufacturing, supply chain, compliance, regulatory compliance, project management, process research, development and drug product development services to its clients in domestic and international markets," said Guy Sansone, Head of A&M's Healthcare Industry Group.

"The combined expertise of A&M and Rondaxe positions our integrated team as a ‘go to' player for full service pharmaceutical consulting services. We believe this will better position our clients to mitigate risk, accelerate speed to market, and drive cost effectiveness in progressing clinical candidates to partnering and commercialization" said Kenton Shultis, CEO of Rondaxe.

About Alvarez & Marsal:

Alvarez & Marsal (A&M) is a global professional services firm specializing in turnaround and interim management, performance improvement and business advisory services. A&M delivers specialist operational, consulting and industry expertise to management and investors seeking to overcome challenges, accelerate performance and maximize value across the corporate and investment lifecycles. Founded in 1983, the firm is known for its distinctive restructuring heritage, hands-on approach and relentless focus on execution and results.

A&M's Healthcare Industry Group combines experienced industry leadership with senior consulting professionals who work with management, boards of directors and stakeholders of both investor-owned and non-profit providers, payors and suppliers to improve financial, operational and clinical performance.

A&M delivers independent, fact-based and fresh perspectives to healthcare leaders across the continuum of care. The firm's comprehensive healthcare industry services include strategic advisory; financial, operational and clinical performance improvement; interim, crisis and contract management; turnaround and restructuring, transaction and financial advisory; compliance, governance and investigations. All A&M professionals bring a proven hands-on approach to serving clients, and excel at leadership, problem-solving and value creation.

To learn more about A&M, visit: www.alvarezandmarsal.com. Connect with A&M on LinkedIn. Become a fan of A&M on Facebook. Follow A&M on Twitter.

About Rondaxe Enterprises:

Rondaxe Enterprises is a unique company providing a suite of services that combines expert drug development consulting, in-depth project management leadership, software applications and virtual business development designed specifically for emerging pharmaceutical and biotech companies. Rondaxe is led by three managing partners, a team of experienced industry executives and more than 50 senior advisors, most of whom have 15-30 plus years of industry experience, with a vision and an unflinching dedication to clients' success. Founded in 2003, Rondaxe has enjoyed steady growth based on a proven track record in delivering results, establishing solid relationships with customers, and a strong commitment to expand skills and product offerings as customer's needs expand.

For more information, visit http://www.rondaxe.com

Contacts
Linden Alschuler & Kaplan, Inc. Public Relations
Hannah Arnold/Jennifer Compton, 212-575-4545
or
Alvarez & Marsal
Rebecca Baker, 212-759-4433
Chief Marketing Officer
..

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.